<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36986888</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Antiviral Mechanisms of <i>N</i>-Phenyl Benzamides on Coxsackie Virus A9.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics15031028</ELocationID><Abstract><AbstractText>Enteroviruses are one of the most abundant groups of viruses infecting humans, and yet there are no approved antivirals against them. To find effective antiviral compounds against enterovirus B group viruses, an in-house chemical library was screened. The most effective compounds against Coxsackieviruses B3 (CVB3) and A9 (CVA9) were CL212 and CL213, two <i>N</i>-phenyl benzamides. Both compounds were more effective against CVA9 and CL213 gave a better EC<sub>50</sub> value of 1 µM with high a specificity index of 140. Both drugs were most effective when incubated directly with viruses suggesting that they mainly bound to the virions. A real-time uncoating assay showed that the compounds stabilized the virions and radioactive sucrose gradient as well as TEM confirmed that the viruses stayed intact. A docking assay, taking into account larger areas around the 2-and 3-fold axes of CVA9 and CVB3, suggested that the hydrophobic pocket gives the strongest binding to CVA9 but revealed another binding site around the 3-fold axis which could contribute to the binding of the compounds. Together, our data support a direct antiviral mechanism against the virus capsid and suggest that the compounds bind to the hydrophobic pocket and 3-fold axis area resulting in the stabilization of the virion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laajala</LastName><ForeName>Mira</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3981-280X</Identifier><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalander</LastName><ForeName>Kerttu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Consalvi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6562-7686</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amamuddy</LastName><ForeName>Olivier Sheik</ForeName><Initials>OS</Initials><Identifier Source="ORCID">0000-0002-1781-1382</Identifier><AffiliationInfo><Affiliation>Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, Makhanda 6140, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Özlem Tastan</ForeName><Initials>ÖT</Initials><Identifier Source="ORCID">0000-0001-6861-7849</Identifier><AffiliationInfo><Affiliation>Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, Makhanda 6140, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biava</LastName><ForeName>Mariangela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poce</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7466-8861</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marjomäki</LastName><ForeName>Varpu</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4592-5926</Identifier><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>336487</GrantID><Agency>Academy of Finland</Agency><Country /></Grant><Grant><Agency>Jane and Aatos Erkko Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">N-phenyl benzamide</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">capsid binder</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>2</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36986888</ArticleId><ArticleId IdType="pmc">PMC10058015</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics15031028</ArticleId><ArticleId IdType="pii">pharmaceutics15031028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Laitinen O.H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M.M., Huhtala H., Ruokoranta T., Lecouturier V., André P., Harju R., et al. Coxsackievirus B1 Is Associated with Induction of β-Cells Autoimmunity That Portends Type 1 Diabetes. Diabetes. 2014;63:446–455. doi: 10.2337/db13-0619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M., Alfthan G., Jousilahti P., Kimpimäki M., Hovi T., Tuomilehto J. Enterovirus Infections as a Possible Risk Factor for Myocardial Infarction. Circulation. 1998;98:2534–2537. doi: 10.1161/01.CIR.98.23.2534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.98.23.2534</ArticleId><ArticleId IdType="pubmed">9843459</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriushkova N.G., Turchyna N.S., Poniatowski V.A., Dolinchuk L.V., Melnyk V.V., Shyrobokov V.P., Zakharchenko N.V. The Role of the Persistent Enterovirus Infection in Development of Acute Stroke. Wiad. Lek. 2017;70:187–191.</Citation><ArticleIdList><ArticleId IdType="pubmed">28511156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui A., Yu D., Zhu Z., Meng L., Li H., Liu J., Liu G., Mao N., Xu W. An Outbreak of Aseptic Meningitis Caused by Coxsackievirus A9 in Gansu, the People’s Republic of China. Virol. J. 2010;7:72. doi: 10.1186/1743-422X-7-72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-72</ArticleId><ArticleId IdType="pmc">PMC2907575</ArticleId><ArticleId IdType="pubmed">20367886</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau B., Bastedo C., Michel R.P., Ghali P. Hepatitis and Encephalitis Due to Coxsackie Virus A9 in an Adult. Case Rep. Gastroenterol. 2011;5:617–622. doi: 10.1159/000333135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000333135</ArticleId><ArticleId IdType="pmc">PMC3220896</ArticleId><ArticleId IdType="pubmed">22114569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung P.K.M., Yuan J., Zhang H.M., Chau D., Yanagawa B., Suarez A., McManus B., Yang D. Specific Interactions of Mouse Organ Proteins with the 5′untranslated Region of Coxsackievirus B3: Potential Determinants of Viral Tissue Tropism. J. Med. Virol. 2005;77:414–424. doi: 10.1002/jmv.20470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20470</ArticleId><ArticleId IdType="pubmed">16173012</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Maher K., Schnurr D., Flemister M.R., Lovchik J.C., Peters H., Sessions W., Kirk C., Chatterjee N., Fuller S., et al. Enterovirus 68 Is Associated with Respiratory Illness and Shares Biological Features with Both the Enteroviruses and the Rhinoviruses. J. Gen. Virol. 2004;85:2577–2584. doi: 10.1099/vir.0.79925-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79925-0</ArticleId><ArticleId IdType="pubmed">15302951</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlenbachs A., Bhatnagar J., Zaki S.R. Tissue Tropism, Pathology and Pathogenesis of Enterovirus Infection. J. Pathol. 2015;235:217–228. doi: 10.1002/path.4438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4438</ArticleId><ArticleId IdType="pubmed">25211036</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the Future: Advances in Development of Broad-Spectrum Capsid-Binding Inhibitors of Enteroviruses. Eur. J. Med. Chem. 2019;178:606–622. doi: 10.1016/j.ejmech.2019.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.06.008</ArticleId><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkki P., Laajala M., Flodström-Tullberg M., Marjomäki V. Human Enterovirus Group B Viruses Rely on Vimentin Dynamics for Efficient Processing of Viral Nonstructural Proteins. J. Virol. 2020;94:e01393-19. doi: 10.1128/JVI.01393-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01393-19</ArticleId><ArticleId IdType="pmc">PMC6955253</ArticleId><ArticleId IdType="pubmed">31619557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruokolainen V., Laajala M., Marjomäki V. Real-Time Fluorescence Measurement of Enterovirus Uncoating. Bio. Protoc. 2020;10:e3582. doi: 10.21769/BioProtoc.3582.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.3582</ArticleId><ArticleId IdType="pmc">PMC7842371</ArticleId><ArticleId IdType="pubmed">33659552</ArticleId></ArticleIdList></Reference><Reference><Citation>Myllynen M., Kazmertsuk A., Marjomäki V. A Novel Open and Infectious Form of Echovirus 1. J. Virol. 2016;90:6759–6770. doi: 10.1128/JVI.00342-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00342-16</ArticleId><ArticleId IdType="pmc">PMC4944302</ArticleId><ArticleId IdType="pubmed">27194757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanwell M.D., Curtis D.E., Lonie D.C., Vandermeerschd T., Zurek E., Hutchison G.R. Avogadro: An Advanced Semantic Chemical Editor, Visualization, and Analysis Platform. J. Cheminform. 2012;4:17. doi: 10.1186/1758-2946-4-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-2946-4-17</ArticleId><ArticleId IdType="pmc">PMC3542060</ArticleId><ArticleId IdType="pubmed">22889332</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Huey R., Linkstrom W., Sanner M., Belew R., Goodsell D., Olson A.J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2010;31:2785–2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan N.M., Alhossary A.A., Mu Y., Kwoh C.K. Protein-Ligand Blind Docking Using QuickVina-W with Inter-Process Spatio-Temporal Integration. Sci. Rep. 2017;7:15451. doi: 10.1038/s41598-017-15571-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-15571-7</ArticleId><ArticleId IdType="pmc">PMC5684369</ArticleId><ArticleId IdType="pubmed">29133831</ArticleId></ArticleIdList></Reference><Reference><Citation>Reshamwala D., Shroff S., Sheik Amamuddy O., Laquintana V., Denora N., Zacheo A., Lampinen V., Hytonen V.P., Tastan Bishop Ö., Krol S., et al. Polyphenols Epigallocatechin Gallate and Resveratrol, and Polyphenol-Functionalized Nanoparticles Prevent Enterovirus Infection through Clustering and Stabilization of the Viruses. Pharmaceutics. 2021;13:1182. doi: 10.3390/pharmaceutics13081182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13081182</ArticleId><ArticleId IdType="pmc">PMC8398301</ArticleId><ArticleId IdType="pubmed">34452144</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeliger D., de Groot B.L. Ligand Docking and Binding Site Analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 2010;24:417–422. doi: 10.1007/s10822-010-9352-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-010-9352-6</ArticleId><ArticleId IdType="pmc">PMC2881210</ArticleId><ArticleId IdType="pubmed">20401516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruokolainen V., Domanska A., Laajala M., Pelliccia M., Butcher S.J., Marjomäki V. Extracellular Albumin and Endosomal Ions Prime Enterovirus Particles for Uncoating That Can Be Prevented by Fatty Acid Saturation. J. Virol. 2019;93:e00599-19. doi: 10.1128/JVI.00599-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00599-19</ArticleId><ArticleId IdType="pmc">PMC6694817</ArticleId><ArticleId IdType="pubmed">31189702</ArticleId></ArticleIdList></Reference><Reference><Citation>Laajala M., Reshamwala D., Marjomäki V. Therapeutic Targets for Enterovirus Infections. Expert Opin. Ther. Targets. 2020;24:745–757. doi: 10.1080/14728222.2020.1784141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1784141</ArticleId><ArticleId IdType="pubmed">32552314</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen M., Waris M., Kajander R., Hyypiä T., Marjomäki V. Coxsackievirus A9 Infects Cells via Nonacidic Multivesicular Bodies. J. Virol. 2014;88:5138–5151. doi: 10.1128/JVI.03275-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03275-13</ArticleId><ArticleId IdType="pmc">PMC3993817</ArticleId><ArticleId IdType="pubmed">24574401</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Tull T.M., Seipel M.E., Groarke J.M. Activity of Pleconaril against Enteroviruses. Antimicrob. Agents Chemother. 1999;43:2109–2115. doi: 10.1128/AAC.43.9.2109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.9.2109</ArticleId><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson K.G., Brown R.N., Cameron R., Chalmers D.K., Hamilton S., Jin B., Krippner G.Y., Luttick A., McConnell D.B., Reece P.A., et al. An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus. J. Med. Chem. 2003;46:3181–3184. doi: 10.1021/jm0202876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0202876</ArticleId><ArticleId IdType="pubmed">12852746</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries K., Dewindt B., Snoeks J., Willebrords R., van Eemeren K., Stokbroekx R., Janssen P.A.J. In Vitro Activity of Pirodavir (R 77975), a Substituted Phenoxy- Pyridazinamine with Broad-Spectrum Antipicornaviral Activity. Antimicrob. Agents Chemother. 1992;36:100–107. doi: 10.1128/AAC.36.1.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.1.100</ArticleId><ArticleId IdType="pmc">PMC189235</ArticleId><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Buontempo P.J., Cox S., Wright-Minogue J., DeMartino J.L., Skelton A.M., Ferrari E., Albin R., Rozhon E.J., Girijavallabhan V., Modlin J.F., et al. SCH 48973: A Potent, Broad-Spectrum, Antienterovirus Compound. Antimicrob. Agents Chemother. 1997;41:1220–1225. doi: 10.1128/AAC.41.6.1220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.41.6.1220</ArticleId><ArticleId IdType="pmc">PMC163890</ArticleId><ArticleId IdType="pubmed">9174174</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Moore D., Anderson B., Pallansch M.A., Pevear D.C., Collett M.S. In Vitro Antiviral Activity of V-073 against Polioviruses. Antimicrob. Agents Chemother. 2009;53:4501–4503. doi: 10.1128/AAC.00671-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00671-09</ArticleId><ArticleId IdType="pmc">PMC2764203</ArticleId><ArticleId IdType="pubmed">19635956</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarov V.A., Braun H., Richter M., Riabova O.B., Kirchmair J., Kazakova E.S., Seidel N., Wutzler P., Schmidtke M. Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses. ChemMedChem. 2015;10:1629–1634. doi: 10.1002/cmdc.201500304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201500304</ArticleId><ArticleId IdType="pmc">PMC4600222</ArticleId><ArticleId IdType="pubmed">26260222</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R., Geraets J.A., Ma Y., Mirabelli C., Flatt J.W., Domanska A., Delang L., Jochmans D., Kumar T.A., Jayaprakash V., et al. A Novel Druggable Interprotomer Pocket in the Capsid of Rhino-and Enteroviruses. PLoS Biol. 2019;17:e3000281. doi: 10.1371/journal.pbio.3000281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000281</ArticleId><ArticleId IdType="pmc">PMC6559632</ArticleId><ArticleId IdType="pubmed">31185007</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M., Hammerschmidt E., Schüler S., Zell R., Birch-Hirschfeld E., Makarov V.A., Riabova O.B., Wutzler P. Susceptibility of Coxsackievirus B3 Laboratory Strains and Clinical Isolates to the Capsid Function Inhibitor Pleconaril: Antiviral Studies with Virus Chimeras Demonstrate the Crucial Role of Amino Acid 1092 in Treatment. J. Antimicrob. Chemother. 2005;56:648–656. doi: 10.1093/jac/dki263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki263</ArticleId><ArticleId IdType="pubmed">16150864</ArticleId></ArticleIdList></Reference><Reference><Citation>Groarke J.M., Pevear D.C. Attenuated Virulence of Pleconaril-Resistant Coxsackievirus B3 Variants. J. Infect. Dis. 1999;179:1538–1541. doi: 10.1086/314758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314758</ArticleId><ArticleId IdType="pubmed">10228078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>